RNA-seq of CYR61-treated human umbilical vein endothelial cells

We assess the effect of CYR61 treatment on the transcriptome of human umbilical vein endothelial cells. We used primary human umbilical vein endothelial cells (HUVECs) from ATCC (PCS-100-010). These cells were maintained according to the manufacturer's recommended instructions. We treated HUVECs with recombinant human CYR61 (PeproTech 120-25): 0.00, 0.05, 0.50, and 5.00 μg/ml for 24 hr. After incubation, we washed cells with PBS, isolated total RNA, and prepared samples for RNA-sequencing.

本研究评估了CYR61处理对人脐静脉内皮细胞转录组的影响。我们使用了源自ATCC（货号PCS-100-010）的原代人脐静脉内皮细胞（HUVECs），并严格按照厂商推荐的操作指南进行细胞培养。我们以浓度分别为0.00、0.05、0.50及5.00 μg/ml的重组人CYR61（PeproTech 货号120-25）处理HUVECs，处理时长为24小时。孵育结束后，我们用磷酸盐缓冲液（PBS）洗涤细胞，提取总RNA，并制备用于RNA测序的样本。